Endogenous dopaminergic tone and dopamine agonist action.
Identifieur interne : 000329 ( Ncbi/Checkpoint ); précédent : 000328; suivant : 000330Endogenous dopaminergic tone and dopamine agonist action.
Auteurs : S A Treseder [Royaume-Uni] ; L A Smith ; P. JennerSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2000.
English descriptors
- KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (adverse effects), Adamantane (analogs & derivatives), Adamantane (pharmacology), Animals, Antiparkinson Agents (pharmacology), Apomorphine (pharmacology), Benzopyrans (pharmacology), Callithrix, Dopamine Agents (adverse effects), Dopamine Agents (pharmacology), Dopamine Agonists (pharmacology), Dyskinesia, Drug-Induced (drug therapy), Dyskinesia, Drug-Induced (physiopathology), Enzyme Inhibitors (adverse effects), Female, Levodopa (metabolism), Levodopa (pharmacology), Locomotion (drug effects), Male, Quinpirole (pharmacology), Receptors, Dopamine D1 (agonists), Receptors, Dopamine D1 (drug effects), Receptors, Dopamine D2 (agonists), Receptors, Dopamine D2 (drug effects), Tyrosine 3-Monooxygenase (antagonists & inhibitors), alpha-Methyltyrosine (adverse effects).
- MESH :
- chemical , adverse effects : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Dopamine Agents, Enzyme Inhibitors, alpha-Methyltyrosine.
- chemical , agonists : Receptors, Dopamine D1, Receptors, Dopamine D2.
- chemical , analogs & derivatives : Adamantane.
- chemical , antagonists & inhibitors : Tyrosine 3-Monooxygenase.
- chemical , drug effects : Receptors, Dopamine D1, Receptors, Dopamine D2.
- chemical , metabolism : Levodopa.
- chemical , pharmacology : Adamantane, Antiparkinson Agents, Apomorphine, Benzopyrans, Dopamine Agents, Dopamine Agonists, Levodopa, Quinpirole.
- drug effects : Locomotion.
- drug therapy : Dyskinesia, Drug-Induced.
- physiopathology : Dyskinesia, Drug-Induced.
- Animals, Callithrix, Female, Male.
Abstract
Dopamine receptor agonists provide symptomatic relief in the early stages of Parkinson's disease, but with disease progression, their efficacy decreases. The reason behind this decrease in effectiveness is unknown, but maximal efficacy may be dependent on endogenous dopaminergic tone to provide stimulation of D1 and D2 receptor subtypes. Therefore, we have investigated the effects of the tyrosine hydroxylase inhibitor alpha-methyl-p-tyrosine (AMPT) on the actions of D1, D2, and D1/D2 agonists and levodopa (L-dopa) in common marmosets treated with 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Administration of AMPT alone further increased motor disability and decreased locomotor activity. Administration of L-dopa reversed motor disability and increased locomotor activity, and this reversal was not affected by previous AMPT treatment. The D1 agonist A-77636 and the D2 agonist quinpirole reversed motor deficits, but these effects were markedly inhibited by previous AMPT treatment. Administration of quinpirole with A-77636 produced a reversal of motor deficits that was more resistant to AMPT pretreatment than was the effect produced by quinpirole or A-77636 alone. These data suggest that D1 and D2 receptor stimulation are required for dopamine receptor agonists to produce a maximal antiparkinsonian response. The reversal of motor deficits produced by the mixed D1/D2 agonist apomorphine was more resistant to AMPT treatment than that produced by quinpirole or A-77636. However, the motor effects of A-77636 plus quinpirole and of apomorphine were still affected by AMPT treatment. This suggests that loss of tyrosine hydroxylase activity may also alter motor activity through inhibition of endogenous L-dopa or norepinephrine synthesis, because both are also involved in the genesis of motor activity.
PubMed: 11009183
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003F22
- to stream PubMed, to step Curation: 003F22
- to stream PubMed, to step Checkpoint: 003F89
- to stream Ncbi, to step Merge: 000329
- to stream Ncbi, to step Curation: 000329
Links to Exploration step
pubmed:11009183Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Endogenous dopaminergic tone and dopamine agonist action.</title>
<author><name sortKey="Treseder, S A" sort="Treseder, S A" uniqKey="Treseder S" first="S A" last="Treseder">S A Treseder</name>
<affiliation wicri:level="1"><nlm:affiliation>Neurodegenerative Disease Research Centre, Guy's, King's, and St. Thomas's School of Biomedical Sciences, King's College London, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Neurodegenerative Disease Research Centre, Guy's, King's, and St. Thomas's School of Biomedical Sciences, King's College London</wicri:regionArea>
<wicri:noRegion>King's College London</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Smith, L A" sort="Smith, L A" uniqKey="Smith L" first="L A" last="Smith">L A Smith</name>
</author>
<author><name sortKey="Jenner, P" sort="Jenner, P" uniqKey="Jenner P" first="P" last="Jenner">P. Jenner</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2000">2000</date>
<idno type="RBID">pubmed:11009183</idno>
<idno type="pmid">11009183</idno>
<idno type="wicri:Area/PubMed/Corpus">003F22</idno>
<idno type="wicri:Area/PubMed/Curation">003F22</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003F89</idno>
<idno type="wicri:Area/Ncbi/Merge">000329</idno>
<idno type="wicri:Area/Ncbi/Curation">000329</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000329</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Endogenous dopaminergic tone and dopamine agonist action.</title>
<author><name sortKey="Treseder, S A" sort="Treseder, S A" uniqKey="Treseder S" first="S A" last="Treseder">S A Treseder</name>
<affiliation wicri:level="1"><nlm:affiliation>Neurodegenerative Disease Research Centre, Guy's, King's, and St. Thomas's School of Biomedical Sciences, King's College London, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Neurodegenerative Disease Research Centre, Guy's, King's, and St. Thomas's School of Biomedical Sciences, King's College London</wicri:regionArea>
<wicri:noRegion>King's College London</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Smith, L A" sort="Smith, L A" uniqKey="Smith L" first="L A" last="Smith">L A Smith</name>
</author>
<author><name sortKey="Jenner, P" sort="Jenner, P" uniqKey="Jenner P" first="P" last="Jenner">P. Jenner</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2000" type="published">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (adverse effects)</term>
<term>Adamantane (analogs & derivatives)</term>
<term>Adamantane (pharmacology)</term>
<term>Animals</term>
<term>Antiparkinson Agents (pharmacology)</term>
<term>Apomorphine (pharmacology)</term>
<term>Benzopyrans (pharmacology)</term>
<term>Callithrix</term>
<term>Dopamine Agents (adverse effects)</term>
<term>Dopamine Agents (pharmacology)</term>
<term>Dopamine Agonists (pharmacology)</term>
<term>Dyskinesia, Drug-Induced (drug therapy)</term>
<term>Dyskinesia, Drug-Induced (physiopathology)</term>
<term>Enzyme Inhibitors (adverse effects)</term>
<term>Female</term>
<term>Levodopa (metabolism)</term>
<term>Levodopa (pharmacology)</term>
<term>Locomotion (drug effects)</term>
<term>Male</term>
<term>Quinpirole (pharmacology)</term>
<term>Receptors, Dopamine D1 (agonists)</term>
<term>Receptors, Dopamine D1 (drug effects)</term>
<term>Receptors, Dopamine D2 (agonists)</term>
<term>Receptors, Dopamine D2 (drug effects)</term>
<term>Tyrosine 3-Monooxygenase (antagonists & inhibitors)</term>
<term>alpha-Methyltyrosine (adverse effects)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term>
<term>Dopamine Agents</term>
<term>Enzyme Inhibitors</term>
<term>alpha-Methyltyrosine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="agonists" xml:lang="en"><term>Receptors, Dopamine D1</term>
<term>Receptors, Dopamine D2</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Adamantane</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Tyrosine 3-Monooxygenase</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Dopamine D1</term>
<term>Receptors, Dopamine D2</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Adamantane</term>
<term>Antiparkinson Agents</term>
<term>Apomorphine</term>
<term>Benzopyrans</term>
<term>Dopamine Agents</term>
<term>Dopamine Agonists</term>
<term>Levodopa</term>
<term>Quinpirole</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Locomotion</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Callithrix</term>
<term>Female</term>
<term>Male</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Dopamine receptor agonists provide symptomatic relief in the early stages of Parkinson's disease, but with disease progression, their efficacy decreases. The reason behind this decrease in effectiveness is unknown, but maximal efficacy may be dependent on endogenous dopaminergic tone to provide stimulation of D1 and D2 receptor subtypes. Therefore, we have investigated the effects of the tyrosine hydroxylase inhibitor alpha-methyl-p-tyrosine (AMPT) on the actions of D1, D2, and D1/D2 agonists and levodopa (L-dopa) in common marmosets treated with 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Administration of AMPT alone further increased motor disability and decreased locomotor activity. Administration of L-dopa reversed motor disability and increased locomotor activity, and this reversal was not affected by previous AMPT treatment. The D1 agonist A-77636 and the D2 agonist quinpirole reversed motor deficits, but these effects were markedly inhibited by previous AMPT treatment. Administration of quinpirole with A-77636 produced a reversal of motor deficits that was more resistant to AMPT pretreatment than was the effect produced by quinpirole or A-77636 alone. These data suggest that D1 and D2 receptor stimulation are required for dopamine receptor agonists to produce a maximal antiparkinsonian response. The reversal of motor deficits produced by the mixed D1/D2 agonist apomorphine was more resistant to AMPT treatment than that produced by quinpirole or A-77636. However, the motor effects of A-77636 plus quinpirole and of apomorphine were still affected by AMPT treatment. This suggests that loss of tyrosine hydroxylase activity may also alter motor activity through inhibition of endogenous L-dopa or norepinephrine synthesis, because both are also involved in the genesis of motor activity.</div>
</front>
</TEI>
<affiliations><list><country><li>Royaume-Uni</li>
</country>
</list>
<tree><noCountry><name sortKey="Jenner, P" sort="Jenner, P" uniqKey="Jenner P" first="P" last="Jenner">P. Jenner</name>
<name sortKey="Smith, L A" sort="Smith, L A" uniqKey="Smith L" first="L A" last="Smith">L A Smith</name>
</noCountry>
<country name="Royaume-Uni"><noRegion><name sortKey="Treseder, S A" sort="Treseder, S A" uniqKey="Treseder S" first="S A" last="Treseder">S A Treseder</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000329 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 000329 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Ncbi |étape= Checkpoint |type= RBID |clé= pubmed:11009183 |texte= Endogenous dopaminergic tone and dopamine agonist action. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:11009183" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
This area was generated with Dilib version V0.6.23. |